BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

675 related articles for article (PubMed ID: 29964204)

  • 1. Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway.
    Xiao Y; Li Y; Tao H; Humphries B; Li A; Jiang Y; Yang C; Luo R; Wang Z
    Cancer Lett; 2018 Oct; 433():199-209. PubMed ID: 29964204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis.
    Li Y; Xiao Y; Lin HP; Reichel D; Bae Y; Lee EY; Jiang Y; Huang X; Yang C; Wang Z
    Biomaterials; 2019 Jan; 188():160-172. PubMed ID: 30352320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SNHG3 silencing suppresses the malignant development of triple-negative breast cancer cells by regulating miRNA-326/integrin α5 axis and inactivating Vav2/Rac1 signaling pathway.
    Wang P; Liu GZ; Wang JF; Du YY
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5481-5492. PubMed ID: 32495883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis.
    Humphries B; Wang Z; Oom AL; Fisher T; Tan D; Cui Y; Jiang Y; Yang C
    Carcinogenesis; 2014 Oct; 35(10):2254-63. PubMed ID: 24925028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
    Chen LL; Zhang ZJ; Yi ZB; Li JJ
    Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
    Guo GC; Wang JX; Han ML; Zhang LP; Li L
    Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers.
    De P; Carlson JH; Jepperson T; Willis S; Leyland-Jones B; Dey N
    Oncotarget; 2017 Jan; 8(2):3072-3103. PubMed ID: 27902969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-1976 knockdown promotes epithelial-mesenchymal transition and cancer stem cell properties inducing triple-negative breast cancer metastasis.
    Wang J; Li M; Han X; Wang H; Wang X; Ma G; Xia T; Wang S
    Cell Death Dis; 2020 Jul; 11(7):500. PubMed ID: 32620748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long noncoding RNA GAS5 suppresses triple negative breast cancer progression through inhibition of proliferation and invasion by competitively binding miR-196a-5p.
    Li S; Zhou J; Wang Z; Wang P; Gao X; Wang Y
    Biomed Pharmacother; 2018 Aug; 104():451-457. PubMed ID: 29793177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer.
    Wang PS; Chou CH; Lin CH; Yao YC; Cheng HC; Li HY; Chuang YC; Yang CN; Ger LP; Chen YC; Lin FC; Shen TL; Hsiao M; Lu PJ
    Oncogene; 2018 Aug; 37(34):4662-4678. PubMed ID: 29755127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-136 suppresses tumor invasion and metastasis by targeting RASAL2 in triple-negative breast cancer.
    Yan M; Li X; Tong D; Han C; Zhao R; He Y; Jin X
    Oncol Rep; 2016 Jul; 36(1):65-71. PubMed ID: 27108696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-4319 Suppress the Malignancy of Triple-Negative Breast Cancer by Regulating Self-Renewal and Tumorigenesis of Stem Cells.
    Chu J; Li Y; Fan X; Ma J; Li J; Lu G; Zhang Y; Huang Y; Li W; Huang X; Fu Z; Yin Y; Yuan H
    Cell Physiol Biochem; 2018; 48(2):593-604. PubMed ID: 30021199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrin α9 depletion promotes β-catenin degradation to suppress triple-negative breast cancer tumor growth and metastasis.
    Wang Z; Li Y; Xiao Y; Lin HP; Yang P; Humphries B; Gao T; Yang C
    Int J Cancer; 2019 Nov; 145(10):2767-2780. PubMed ID: 31008533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARHGAP18 Downregulation by miR-200b Suppresses Metastasis of Triple-Negative Breast Cancer by Enhancing Activation of RhoA.
    Humphries B; Wang Z; Li Y; Jhan JR; Jiang Y; Yang C
    Cancer Res; 2017 Aug; 77(15):4051-4064. PubMed ID: 28619708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5.
    Zhou W; Song F; Wu Q; Liu R; Wang L; Liu C; Peng Y; Mao S; Feng J; Chen C
    PLoS One; 2017; 12(4):e0176395. PubMed ID: 28437471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-137 Suppresses Triple-Negative Breast Cancer Stemness and Tumorigenesis by Perturbing BCL11A-DNMT1 Interaction.
    Chen F; Luo N; Hu Y; Li X; Zhang K
    Cell Physiol Biochem; 2018; 47(5):2147-2158. PubMed ID: 29975921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
    Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
    BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-212-5p Suppresses the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer by Targeting Prrx2.
    Lv ZD; Yang DX; Liu XP; Jin LY; Wang XG; Yang ZC; Liu D; Zhao JJ; Kong B; Li FN; Wang HB
    Cell Physiol Biochem; 2017; 44(5):1785-1795. PubMed ID: 29216628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-124 regulates EMT based on ZEB2 target to inhibit invasion and metastasis in triple-negative breast cancer.
    Ji H; Sang M; Liu F; Ai N; Geng C
    Pathol Res Pract; 2019 Apr; 215(4):697-704. PubMed ID: 30611621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
    Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
    Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.